Evidence map›Paper›PMID 30600364›Full record

ArticleWorld journal of surgery2019

Chemoprevention with Somatuline© Delays the Progression of Pancreatic Neuroendocrine Neoplasms in a Mouse Model of Multiple Endocrine Neoplasia Type 1 (MEN1).

Caroline L Lopez, Barbara Joos, Detlef K Bartsch, Jerena Manoharan, Max Albers, Emily P Slater, Carmen Bollmann, Sylvia Roth, Aninja Bayer, Volker Fendrich

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. HeterozygousAdvances in respiratory medicine · 2025
    Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Caroline L LopezDepartment of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany.
Barbara JoosDepartment of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany.
Detlef K BartschDepartment of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany.
Jerena ManoharanDepartment of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany.
Max AlbersDepartment of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany.
Emily P SlaterDepartment of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany.
Carmen BollmannDepartment of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany.
Sylvia RothDepartment of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany.
Aninja BayerDepartment of Visceral, Thoracic and Vascular Surgery, Philipps University Marburg, Baldingerstrasse, 35041, Marburg, Germany.
Volker FendrichDepartment of Endocrine Surgery, Schön Klinik Hamburg Eilbek, Dehnhaide 120, 22081, Hamburg, Germany. fendrich@schoen-kliniken.de.
Philipps University of Marburg · DESchön Klinik Hamburg Eilbek · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveLong-acting synthetic somatostatin analogues (SSA) are an essential part of the treatment of neuroendocrine neoplasms. We evaluated the chemopreventive effects of a long-acting somatostatin analogue on the development of pancreatic neuroendocrine neoplasms (pNENs) in a genetically engineered MEN1 knockout mouse model. MATERIALS AND

methodsHeterozygote MEN1 knockout mice were injected every 28 days subcutaneously with the somatostatin analogue lanreotide (Somatuline Autogel©; Ipsen Pharma) or a placebo starting at day 35 after birth. Mice were euthanized after 6, 9, 12, 15 and 18 months, and the size and number of pNENs were measured due histological analysis and compared to the placebo group.

resultsThe median tumor size of pNENs was statistically significantly smaller after 9 (control group vs. SSA group; 706.476 µm

conclusionLong-acting somatostatin analogues may be an effective chemopreventive approach to delay the progression of MEN1-associated pNENs. After our preclinical results, we would recommend to evaluate the effects of long-acting SSA in a prospective clinical trial.

Indexed as

AnimalsAntineoplastic AgentsCaspase 3Cell ProliferationChemopreventionDisease Models, AnimalDisease ProgressionKi-67 AntigenMiceMice, KnockoutMultiple Endocrine Neoplasia Type 1Neuroendocrine TumorsPancreatic NeoplasmsPeptides, CyclicProto-Oncogene ProteinsSomatostatinAntineoplastic AgentsCasp3 protein, mouseCaspase 3Ki-67 AntigenlanreotideMen1 protein, mouseMki67 protein, mousePeptides, CyclicProto-Oncogene ProteinsSomatostatin

Identifiers

PMID30600364
OpenAlexW2907556473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.